Unknown PHASE2 INTERVENTIONAL NCT00002241

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

A Multicenter, Open-Label, 24-Week Pilot Study to Evaluate the Safety and Efficacy of Indinavir Sulfate 800 Mg b.i.d. in Combination With Ritonavir 100 Mg/d4T/3TC b.i.d. in HIV-Infected Individuals

Sponsor: Merck Sharp & Dohme LLC

Conditions HIV Infections

Interventions Indinavir sulfate Lamivudine Ritonavir Stavudine

Updated 7 times since 2017 Last updated: Jun 23, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates HIV Infections and is currently ongoing. Merck Sharp & Dohme LLC leads this study, which shows 7 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jun 2022 — Jul 2024 [monthly]

Unknown Status PHASE2
Jan 2021 — Jun 2022 [monthly]

Unknown Status PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Birmingham, United States , Brookline, United States , Brooklyn, United States , Chicago, United States , Houston, United States , Miami, United States , New Orleans, United States , New York, United States , Philadelphia, United States , San Diego, United States and 2 more locations